Neurocrine Biosciences (NBIX) – Investment Analysts’ Weekly Ratings Changes

Neurocrine Biosciences (NASDAQ: NBIX) recently received a number of ratings updates from brokerages and research firms:

• 7/21/2026 – Neurocrine Biosciences had its price target raised by Guggenheim from $175.00 to $200.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Neurocrine Biosciences had its price target raised by Wells Fargo & Company from $175.00 to $200.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – Neurocrine Biosciences had its price target raised by Truist Financial Corporation from $155.00 to $200.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Neurocrine Biosciences had its price target raised by BMO Capital Markets from $144.00 to $170.00. They now have a “market perform” rating on the stock.
• 7/10/2026 – Neurocrine Biosciences was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 7/7/2026 – Neurocrine Biosciences had its price target raised by Royal Bank Of Canada from $183.00 to $195.00. They now have an “outperform” rating on the stock.
• 6/24/2026 – Neurocrine Biosciences was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 6/23/2026 – Neurocrine Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/3/2026 – Neurocrine Biosciences was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 6/2/2026 – Neurocrine Biosciences is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $213.00 price target on the stock.
• 5/29/2026 – Neurocrine Biosciences had its price target raised by Royal Bank Of Canada from $180.00 to $183.00. They now have an “outperform” rating on the stock.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 245,088 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total value of $37,824,431.04. Following the completion of the sale, the director owned 511,293 shares in the company, valued at approximately $78,907,848.69. The trade was a 32.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $157.65, for a total value of $2,364,750.00. Following the completion of the sale, the director directly owned 34,480 shares of the company’s stock, valued at $5,435,772. The trade was a 30.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 394,172 shares of company stock valued at $62,221,181 over the last 90 days. 4.60% of the stock is owned by insiders.

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.